Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Blueprint Medicines (BPMC) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Kate Haviland will deliver a corporate overview and present the company's 2025 outlook on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).

The presentation will be accessible through a live webcast on the Investors & Media section of Blueprint Medicines' website. Interested parties can access the replay, which will remain available on the company's website for 30 days after the presentation.

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT^®/AYVAKYT^® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

Trademarks

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334060.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines (BPMC) presenting at the 2025 J.P. Morgan Healthcare Conference?

Blueprint Medicines will present on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).

How can investors watch Blueprint Medicines' J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast on Blueprint Medicines' website in the Investors & Media section at ir.blueprintmedicines.com.

How long will the BPMC J.P. Morgan Conference presentation replay be available?

The presentation replay will be archived on Blueprint Medicines' website for 30 days following the presentation.

What topics will Blueprint Medicines cover at the 2025 J.P. Morgan Healthcare Conference?

The presentation will include a corporate overview and Blueprint Medicines' 2025 outlook, delivered by CEO Kate Haviland.